Arensia

Exhibitor

ARENSIA is specialized to perform EARLY PATIENT STUDIES in various indications. We run modern Phase I units located in university clinics in Eastern Europe. Our trials imply a high degree of scientific and logistical expertise: e.g. sophisticated designs, biomarkers and long confinement. ARENSIA´s competitive edge are unmatched recruitment speed in a wide range of patient populations and a spotless quality record for complex Phase I (first into patient)/ II/ POC studies. We bring together large patient pools - incl. treatment naïve- in cardiovascular, diabetes/metabolic, gastro-enterology, hepatology, immunology, infectious diseases HCV/HIV, oncology, respiratory, nephrology, urology, with yearlong know-how in early clinical trials. Phase I trials in special patient populations (renal & hepatic impairment) belong to our routine. The regulatory environment is very competitive: 30 days approvals timelines in Moldova and 60 days in Romania and Lithuania. This translates into an invaluable advantage for our clients: working with ARENSIA results in major savings because the clients can reduce the number of sites, as we are able to deliver faster and in a single site.
www.arensia-em.com ›

Co-located with Biomarkers World Europe:

  • Exploratory Clinical Development World Europe 2015